Detalhe da pesquisa
1.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Lancet Oncol
; 23(3): 406-415, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074072
2.
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.
Lancet Haematol
; 4(2): e67-e74, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089238